New Portfolio Startup: EVIIVE
We are happy to welcome the newest startup to our portfolio: EVIIVE, offering a next-generation biomarker discovery platform that delivers precise diagnostics in majority of immuno-oncology diseases by breaking personalized medicine barriers.
Published by
Universitätsspital Zürich
EVIIVE is a Swiss biotech company co-founded by Dr. Kevin Yim and Dr. Richard Chahwan. They are pioneering next-generation liquid biopsy diagnostics by decoding the hidden messages of extracellular vesicles (EVs). Their high-dimensional, single-vesicle profiling platform enables precise prediction of patient response to immunotherapies, starting with advanced melanoma. By turning immune noise into actionable clinical signals, they aim to transform how cancer patients are selected and monitored for treatment.
Besides being a USZ Startup, EVIIVE is a UZH spin-off.
We are delighted to support EVIIVE in revolutionizing the selection of cancer treatments through its two innovative platforms for the discovery of EV biomarkers, IMPASS and IMPACT.
